William Astin, MD
Family Medicine · Bristol, TNNPI 1356310759
Payments from drug & device makers
Across 590 payments — averaging $14.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$946
- Lilly USA, LLC$808
- AbbVie$643
- GSK$505
- Johnson & Johnson$490
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,476100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 122 | $1,652 |
| AstraZeneca | 52 | $946 |
| Lilly USA, LLC | 55 | $808 |
| AbbVie(2 entities) | 54 | $643 |
| GSK | 37 | $505 |
| Johnson & Johnson | 36 | $490 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $404 |
| Novartis | 37 | $394 |
| Merck | 31 | $375 |
| Esperion Therapeutics, Inc. | 17 | $305 |
| Amgen | 16 | $247 |
| Boehringer Ingelheim | 15 | $214 |
| Amarin Pharma, Inc. | 12 | $208 |
| Pfizer | 11 | $168 |
| Bayer | 8 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $119 |
| Sanofi-aventis U.S. LLC | 6 | $93 |
| Exact Sciences | 5 | $83 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $76 |
| Ironwood Pharmaceuticals, Inc | 5 | $75 |
| Dexcom, Inc. | 4 | $70 |
| Corium, LLC | 4 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $59 |
| Antares Pharma, Inc. | 4 | $55 |
| Idorsia Pharmaceuticals US Inc | 2 | $41 |
| Gilead | 2 | $34 |
| Eisai Inc. | 2 | $29 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Inogen, Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,498 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 245 | $185,688 |
| JardianceEmpagliflozin | 132 | $144,596 |
| MounjaroTirzepatide | 82 | $115,109 |
| OzempicSemaglutide | 61 | $68,122 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $51,362 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $43,467 |
| FarxigaDapagliflozin Propanediol | 43 | $38,736 |
| XareltoRivaroxaban | 43 | $35,446 |
| ProliaDenosumab | 19 | $33,522 |
| LinzessLinaclotide | 21 | $22,870 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $15,381 |
| JanuviaSitagliptin Phosphate | 17 | $15,174 |
| Levemir FlexpenInsulin Detemir | 42 | $13,539 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 97 | $13,187 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $12,933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $168 | $185,688245 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $214 | $165,730178 claims |
| Lilly USA, LLCMounjaro | $808 | $115,10982 claims |
| Novo NordiskOzempic, Levemir | $1,652 | $71,77772 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $505 | $54,79187 claims |
| AbbVieLinzess, Synthroid, Restasis | $643 | $38,766131 claims |
| AstraZenecaFarxiga | $946 | $38,73643 claims |
| Johnson & JohnsonXarelto | $490 | $35,44643 claims |
| AmgenProlia | $247 | $33,52219 claims |
| MerckJanuvia, Belsomra | $375 | $22,88334 claims |
| NovartisEntresto | $394 | $9,32012 claims |
| Sanofi-aventis U.S. LLCLantus | $93 | $4,82231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Bristol
- Andrew BrockmyreBristol$1.8M
- Frederick MartinBristol$502K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.